AIM™ platform: A new immunotherapy approach for viral diseases

Area of Science:

• Immunology
• Virology
• Nanotechnology

Background:

• Chronic viral infections like Epstein-Barr virus (EBV), Human T-lymphotropic virus type 1 (HTLV-1), and human papillomavirus (HPV) are linked to malignancies and autoimmune disorders.
• Current treatment options for these viral infections are inadequate.
• T cell-based therapies offer a potential strategy for managing these complex diseases.

Purpose of the Study:

• To evaluate the efficacy of the NexImmune Artificial Immune Modulation (AIM) nanoparticle platform in directing T cell responses against EBV, HTLV-1, and HPV.
• To demonstrate the expansion and functional relevance of multi-antigen-specific CD8+ T cells for adoptive cell therapy.
• To explore the potential of AIM nanoparticles for treating viral infections, cancer, and autoimmune diseases.

Main Methods:

• Utilized AIM nanoparticles ex vivo to enrich and expand (E+E) rare multi-antigen-specific CD8+ T cells.
• Expanded T cells were characterized for memory phenotypes (effector, central, stem-like) and antigen specificity.
• Assessed in vitro cytotoxic activity and polyfunctionality of expanded T cells against antigen-expressing cell lines.

Main Results:

• AIM nanoparticles successfully expanded polyfunctional CD8+ T cells targeting EBV and HPV antigens.
• Expanded T cells exhibited significant in vitro cytotoxic activity against target cells.
• The study demonstrated the functional relevance of targeting EBV, HTLV-1, and HPV using expanded CD8+ T cells.

Conclusions:

• The AIM nanoparticle platform effectively generates antigen-specific T cells for adoptive cell therapy.
• AIM adoptive cell therapies show potential for treating chronic viral infections, cancers like acute myeloid leukemia and multiple myeloma, and autoimmune diseases.
• The injectable AIM nanoparticle platform offers a versatile approach for in vivo modulation of T cell responses.